选择性支气管动脉灌注联合全身静脉给药治疗局部晚期非小细胞肺癌  

The Selective Bronchial Artery Perfusion Combined with Intravenous Administration in the Treatment of Locally Advanced Non-small Cell Lung Cancer

作　　者：周恒根[1] 倪敬中[1] 刘兰芳[1] 程燕[1] 李亚莉[1] 李华年[1] 

机构地区：[1]邳州市人民医院肿瘤科,江苏邳州221300

出　　处：《肿瘤基础与临床》2012年第3期216-218,共3页journal of basic and clinical oncology

摘　　要：目的探讨GP方案双途径给药治疗局部晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法选择NSCLC患者46例,随机分为GP方案双途径给药治疗组(试验组)和GP方案单纯静脉治疗组(对照组),每组23例。试验组:吉西他滨1 000 mg·m-2+顺铂80 mg·m-2,选择性支气管动脉灌注,d1;吉西他滨1 000 mg·m-2静滴,d8。对照组:吉西他滨1 000 mg·m-2静滴,d1,8;顺铂80 mg·m-2静滴,d1。对2组患者的疗效和毒副反应进行比较分析。结果试验组有效率57%、疾病控制率91%、1 a生存率56%、无进展生存期7.6个月、总生存期13.2个月,未出现严重的毒副反应;对照组有效率35%、疾病控制率70%、1 a生存率42%、无进展生存期5.8个月、总生存期10.5个月,未出现严重的毒副反应。试验组有效率、疾病控制率、无进展生存期、总生存期均高于对照组(P均<0.05);1 a生存率、毒副反应2组比较差异无统计学意义(P>0.05)。结论 GP方案双途径给药治疗局部晚期NSCLC临床疗效确切,用药安全,值得临床推广应用。Objective To study the efficacy and safety of double route Administration GP regimen in the treatment of locally advanced non-small cell lung cancer （NSCLC）. Methods All the 46 patients with NSCLC were divided into the test group and the control group,23 cases in each group. The regimen of the test group： gemcitabine 2 . 1 000 mg . n1-2 ＋ cisplatin 80 mg. m-2 ,selective bronchial artery perfusion,dI ;gemcitabine 1 000 mg. m ,intravenous infusion,d8. The regimen of the control group：gemcitabine 1 000 mg. In-2 ,intravenous infusion d1.8 ;cisplatin 80 mg. m-2 ,intravenous infusion, d1. The efficacy and toxicities of the two groups were analyzed comparatively. Results In the test group, the response rate was 57% ,the disease control rate was 91% , 1-year survival rate was 56% , the progression free survival time was 7.6 months,the overall survival time was 13.2 months, no serious toxicities were observed;in the control group, the response rate was 35%, the disease control rate was 70%, 1-year survival rate was 42% ,the progression free survival time was 5.8 months,the overall survival time was 10.5 months,no serious toxicities were observed too. The response rate, the disease control rate, the progression free survival time, the overall survival time of the test group were better than those of the control group （ P 〈 0.05 ）. The 1-year survival rate and the serious toxicities were no significant differences between the two groups （ P 〉 0.05 ）. Conclusion The double route administration GP regimen is effective and safe in the treatment of locally advanced NSCLC, and it is worthy of clinical application.

关 键 词：非小细胞肺癌 支气管动脉 化疗 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]